Abstract P2-09-28: Integrated Gene Expression and MRI Analysis To Assess Early Therapeutic Response to Bevacizumab in Primary Breast Cancer
| العنوان: | Abstract P2-09-28: Integrated Gene Expression and MRI Analysis To Assess Early Therapeutic Response to Bevacizumab in Primary Breast Cancer |
|---|---|
| المؤلفون: | Sonia P. Li, Anwar R. Padhani, R F Adams, NJ Taylor, Francesca M. Buffa, S Mehta, Andreas Makris, N P Hughes, A Adwani, A L Harris, N C Levitt |
| المصدر: | Cancer Research. 70:P2-09 |
| بيانات النشر: | American Association for Cancer Research (AACR), 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Pathology, Chemotherapy, medicine.diagnostic_test, Bevacizumab, Performance status, business.industry, medicine.medical_treatment, Cancer, Magnetic resonance imaging, medicine.disease, Breast cancer, Pharmacokinetics, Internal medicine, medicine, Biomarker (medicine), business, medicine.drug |
| الوصف: | Background: Bevacizumab is an approved drug for advanced breast cancer alongside chemotherapy. To date there is no biomarker proven to be effective in patient stratification. To address this, a window of opportunity study was designed where bevacizumab is administered as a short-term first line treatment with a detailed pharmacodynamic assessment to identify the patients who are most likely to benefit from this therapy. This assessment consisted of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) and gene expression analysis. Method: This is an on going two-centre, Phase II, non-randomised study. 43 locally advanced breast cancer patients aged >18 years, with performance status 0-1 who have adequate bone marrow, renal and liver functions have been enrolled. A single infusion of bevacizumab (15mg/kg) was given prior to commencement of neoadjuvant chemotherapy. DCE-MRI and core biopsies for exon gene array analysis were performed both at baseline and 2 weeks after bevacizumab. Pharmacokinetic modelling of DCE-MRI was used to quantify the volume transfer constant Ktrans, the rate constant kep, and the fractional volume of the extra-vascular extracellular space ve. The median pharmacokinetic parameter values over the tumour volumes of interest were then computed both pre-and post-bevacizumab. Results: Our initial gene expression analysis from 21 patients showed a high variability in the response. This was true for both single gene analysis and pathway signatures. In particular the expression fold changes of hypoxia and proliferation signatures after bevacizumab ranged from a minimum of 0.6 fold decrease to a maximum of 4.3 fold increase. Interestingly, fold changes in both these signatures were significantly positively correlated (Spearman rho=0.81, P Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-28. |
| تدمد: | 1538-7445 0008-5472 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::c472b29cd84cd2b574ce47fc74d472c4 https://doi.org/10.1158/0008-5472.sabcs10-p2-09-28 |
| رقم الأكسشن: | edsair.doi...........c472b29cd84cd2b574ce47fc74d472c4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15387445 00085472 |
|---|